Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 9,467 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrence Clear all
Suspended Phase 2Phase 3 Interventional

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

NCT05107934
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 22, 2026, 6:21 AM EDT
Terminated Not applicable Interventional Results available

Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer

NCT04827732
View directory record Official record
Conditions
Recurrent Rectal Cancer
Interventions
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy, MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Radiation · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 22, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional Results available

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

NCT04377087
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib
Drug
Lead sponsor
Sarah E Taylor
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 22, 2026, 6:21 AM EDT
Not yet recruiting Phase 4 Interventional

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

NCT07018206
View directory record Official record
Conditions
Axial Spondylarthritis (axSpA)
Interventions
Upadacitinib 15 MG [Rinvoq]
Drug
Lead sponsor
CARE ARTHRITIS LTD.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 6:21 AM EDT
Terminated Phase 1 Interventional

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

NCT02833701
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Dietary Supplement · Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 22, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional Results available

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

NCT01808534
View directory record Official record
Conditions
Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor
Interventions
palifosfamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

NCT00103298
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 22, 2026, 6:21 AM EDT
Recruiting Not applicable Interventional

Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker Skin Color

NCT06406621
View directory record Official record
Conditions
Pilonidal Disease
Interventions
Laser hair depilation, Standard of Care (SOC)
Procedure · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 6:21 AM EDT
Recruiting Not applicable Interventional

Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer

NCT07631572
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Cesium-131 Low Dose Radiation (LDR)
Device
Lead sponsor
Denise Fabian
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 6:21 AM EDT
Not listed Phase 2 Interventional

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

NCT00080977
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin
Biological
Lead sponsor
Blumenthal Cancer Center at Carolinas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

NCT00810719
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Erlotinib, gemcitabine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

NCT01158300
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
VEGF inhibitor PTC299
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Early Phase 1 Interventional

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

NCT01737671
View directory record Official record
Conditions
Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions
Ommaya Reservoir, Methotrexate, Leucovorin
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 22 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer

NCT00093834
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, cyclophosphamide, doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 4 Interventional

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

NCT00050999
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome
Interventions
ONTAK
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 22, 2026, 6:21 AM EDT
Not listed Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

NCT00003163
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Cognitive Behavioral Stress Intervention for Women Who Smoke

NCT03077945
View directory record Official record
Conditions
Smoking, Cigarette, Smoking Cessation, Stress, Stress, Emotional, Stress Reaction
Interventions
heart rate variability biofeedback and cognitive reappraisal, control tasks
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth

NCT02913495
View directory record Official record
Conditions
Premature Birth
Interventions
Vaginal Progesterone, Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Springfield, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 22, 2026, 6:21 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation

NCT01326728
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Hodgkins Lymphoma, Non-Hodgkins Lymphoma
Interventions
Allogeneic stem cell transplant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 22, 2026, 6:21 AM EDT
Terminated Phase 1 Interventional

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

NCT02460367
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
Interventions
Docetaxel, Tergenpumatucel-L, Indoximod
Drug · Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
St Louis, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

NCT00994071
View directory record Official record
Conditions
Medulloblastoma, Pontine Glioma, Ependymoma, Astrocytoma, PNET
Interventions
Temozolomide, ABT-888
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 22, 2026, 6:21 AM EDT
Completed No phase listed Observational

Self-Care for Lymphedema in Patients With Breast Cancer

NCT00670644
View directory record Official record
Conditions
Breast Cancer
Interventions
questionnaire administration, survey administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

NCT02626364
View directory record Official record
Conditions
Recurrent/Refractory Glioblastoma
Interventions
crenolanib
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 22, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

NCT00049530
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
PEG-interferon alfa-2b
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Lakeland, Florida • Bloomington, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 22, 2026, 6:21 AM EDT